Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005;11(18):2279-99.
doi: 10.2174/1381612054367300.

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy

Affiliations
Review

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy

Sho-ichi Yamagishi et al. Curr Pharm Des. 2005.

Abstract

Diabetic vascular complication is a leading cause of end-stage renal failure, acquired blindness, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Recent large prospective clinical studies have shown that intensive glucose control reduces effectively microvascular complications among patients with diabetes, and insulin resistance and postprandial hyperglycemia seem to be involved in diabetic macrovascular complications. Chronic hyperglycemia is a major initiator of diabetic vascular complications. Indeed, high glucose, via various mechanisms such as increased production of advanced glycation end products, activation of protein kinase C, stimulation of the polyol pathway and enhanced reactive oxygen species generation, regulates vascular inflammation, altered gene expression of growth factors and cytokines, and platelet and macrophage activation, thus playing a central role in the development and progression of diabetic vascular complications. This article summarizes the molecular mechanisms of diabetic vascular complications and the potential therapeutic interventions that may prevent these disorders even in the presence of hyperglycemia, control of which is often difficult with current therapeutic options.

PubMed Disclaimer

Comment in

  • Vascular complications of diabetes.
    Stenina OI. Stenina OI. Curr Pharm Des. 2005;11(18):2277-8. doi: 10.2174/1381612054367319. Curr Pharm Des. 2005. PMID: 16022667 No abstract available.

MeSH terms

LinkOut - more resources